# Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus

> **NCT00171392** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 132 (actual)

## Conditions studied

- Prevention of Acute Rejection After Kidney Transplantation

## Interventions

- **DRUG:** Enteric-coated mycophenolate sodium

## Key facts

- **NCT ID:** NCT00171392
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2011-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171392, "Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00171392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*